Shandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets

Stock News

03/04

Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1178574727"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178574727\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178574727?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 16:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178574727","market":"us","top_or_hot":-1,"title":"Shandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets","media":"Stock News","content":"<p>Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-04 16:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1178574727","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178574727","pubTimestamp":1772613259,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","00719":"山东新华制药股份"},"translate_title":"山东新华制药获恩他卡朋片药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}